DigiNepal

Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes

Oncology Research · Dade Feng, Huiting Yan, Qian Ni et al. · 2026

  • EnglishRead in your language
  • CitedEvery fact sourced
  • Ad-freeNo ads, no tracking

Quick facts

Author
Dade Feng, Huiting Yan, Qian Ni, Zirui Peng, Xiong Xu, Yanfang Liang, Chongmei Liu ref
Published
ref
Publisher
Tech Science Press ref
Journal
Oncology Research ref

Questions

Who wrote Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes?
Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes was written by Dade Feng, Huiting Yan, Qian Ni, Zirui Peng.
When was Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes first published?
Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes was first published in 2026.

Sources

  1. Publisher record (DOI, via Crossref)

Last updated · facts checked 23 October 2026

Cite this page

"Epigenetic Silencing of ZNF471 Contributes to Osimertinib Resistance in Lung Adenocarcinoma: β-Hydroxybutyrate Associates with ZNF471 Re-Expression and Reduced Resistance-Associated Phenotypes". DigiNepal. Last updated 23 October 2026. https://diginpl.com/books/paper-or-2026-087712. Retrieved 14 November 2026.

Machine-readable versions: JSON · Markdown

Open-access publication. Read it free at the publisher: https://doi.org/10.32604/or.2026.087712.

← Books